Experience in induction and maintenance treatment of new drugs in primary central nervous system lymphoma
-
摘要: 原发中枢神经系统淋巴瘤(PCNSL)是一种罕见的结外非霍奇金淋巴瘤，其发病率低、恶性程度高、预后差，目前仍无标准治疗方案。早期的手术治疗并没有改善患者预后，联合化疗一定程度提高了疗效但血液学毒性较大，自体造血干细胞移植巩固治疗可进一步提高疗效。近年来随着对PCNSL分子生物信息学的研究进展，新型靶向药物在PCNSL应用中显示出了良好的前景。本文介绍了我中心接受新型靶向药物治疗的5例PCNSL的诊治经过，并对新药在PCNSL中的应用进行综述。
-
关键词:
- 原发中枢神经系统淋巴瘤 /
- 新药
Abstract: Primary central nervous system lymphoma(PCNSL) is a rare extranodal non-Hodgkin lymphoma with low incidence, high malignancy, and poor prognosis. Currently, there is no standard treatment. Early surgical treatment did not improve its prognosis, combined chemotherapy improved its efficacy to a certain extent, but had high hematological toxicity. Consolidation therapy with autologous hematopoietic stem cell transplantation could further improve its efficacy. In recent years, with the progress of molecular bioinformatics research on PCNSL, the application of new targeted drugs in PCNSL has shown a good prospect. This article introduces the diagnosis and treatment of 5 cases of PCNSL treated with new targeted drugs in our center, and reviews the application of new drugs in PCNSL.-
Key words:
- primary central nervous system lymphoma /
- new drug
-
-
[1] Yang H, Xun Y, Yang A, et al. Advances and challenges in the treatment of primary central nervous system lymphoma[J]. J Cell Physiol, 2020, 235(12): 9143-9165. doi: 10.1002/jcp.29790
[2] Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases[J]. J Neurosurg, 2000, 92(2): 261-266. doi: 10.3171/jns.2000.92.2.0261
[3] Chiavazza C, Pellerino A, Ferrio F, et al. Primary CNS Lymphomas: Challenges in Diagnosis and Monitoring[J]. Biomed Res Int, 2018, 2018: 3606970.
[4] Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience[J]. J Clin Oncol, 2003, 21(2): 266-272. doi: 10.1200/JCO.2003.09.139
[5] Abrey LE, Ben-Porat L, Panageas KS, et al. Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model[J]. J Clin Oncol, 2006, 24(36): 5711-5715. doi: 10.1200/JCO.2006.08.2941
[6] Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphoma of the brain: can high dose, large volume radiation therapy improve survival? Report on a prospective trial by the Radiation Therapy Oncology Group(RTOG): RTOG 8315[J]. Int J Radiat Oncol Biol Phys, 1992, 23(1): 9-17. doi: 10.1016/0360-3016(92)90538-S
[7] Song Y, Wen Y, Xue W, et al. Effect of rituximab on primary central nervous system lymphoma: a metaanalysis[J]. Int J Hematol, 2017, 106(5): 612-621. doi: 10.1007/s12185-017-2316-z
[8] Bromberg JEC, van der Meulen M, Doorduijn JK. The Role of Rituximab in Primary Central Nervous System Lymphoma[J]. Curr Oncol Rep, 2020, 22(8): 78. doi: 10.1007/s11912-020-00941-8
[9] Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial[J]. Lancet Haematol, 2017, 4(11): 510-523. doi: 10.1016/S2352-3026(17)30174-6
[10] Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or Autologous Stem-Cell Transplantation for Primary CNS Lymphoma in Patients 60 Years of Age and Younger: Results of the Intergroup ANOCEF-GOELAMS Randomized Phase Ⅱ PRECIS Study[J]. J Clin Oncol, 2019, 37(10): 823-833. doi: 10.1200/JCO.18.00306
[11] Grommes C, Pastore A, Palaskas N, et al. Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma[J]. Cancer Discov, 2017, 7(9): 1018-1029. doi: 10.1158/2159-8290.CD-17-0613
[12] Grommes C, Tang SS, Wolfe J, et al. Phase 1b trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma[J]. Blood, 2019, 133(5): 436-445. doi: 10.1182/blood-2018-09-875732
[13] Narita Y, Nagane M, Mishima K, et al. Phase Ⅰ/Ⅱ study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma[J]. Neuro Oncol, 2021, 23(1): 122-133. doi: 10.1093/neuonc/noaa145
[14] Chen F, Pang D, Guo H, et al, Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: A real-world experience of off-label ibrutinib use[J]. Cancer Medicine, 2020, 9(22): 8676-8684. doi: 10.1002/cam4.3499
[15] 宋玉琴, 邓丽娟, 张斌, 等. 奥布替尼在复发/难治原发或继发中枢神经系统淋巴瘤患者的外周血和脑脊液中药物浓度的初步结果[C]. CSCO学术年会论文汇编, 2021: 548-549.
[16] Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary Central Nervous System Lymphoma[J]. Cancer Cell, 2017, 31(6): 833-843. doi: 10.1016/j.ccell.2017.04.012
[17] Grommes C, Pentsova E, Nolan C, et al. Phase Ⅱ study of single agent buparlisib in recurrent / refractory primary(PCNSL)and secondary CNS lymphoma(SCNSL)[Abstract]. Neuro-Oncology, 2016, 15(6): 3.
[18] Korfel A, Schlegel U, Herrlinger U, et al. Phase Ⅱ Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma[J]. J Clin Oncol, 2016, 34(15): 1757-1763. doi: 10.1200/JCO.2015.64.9897
[19] Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalidomide in combination with intravenous rituximab(REVRI)in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase Ⅱ study of the French Oculo-Cerebral lymphoma(LOC)Network and the Lymphoma Study Association(LYSA)[J]. Ann Oncol, 2019, 30(4): 621-628. doi: 10.1093/annonc/mdz032
[20] Tun HW, Johnston PB, DeAngelis LM, et al. Phase 1 study of pomalidomide and dexamethasone for relapsed/refractory primary CNS or vitreoretinal lymphoma[J]. Blood, 2018, 132(21): 2240-2248. doi: 10.1182/blood-2018-02-835496
[21] Rubenstein JL, Geng H, Fraser EJ, et al. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma[J]. Blood Adv, 2018, 2(13): 1595-1607. doi: 10.1182/bloodadvances.2017014845
[22] Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma[J]. Blood, 2017, 129(23): 3071-3073. doi: 10.1182/blood-2017-01-764209
[23] Siddiqi T, Wang X, Blanchard MS, eal. CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma[J]. Blood Adv, 2021, 5(20): 4059-4063. doi: 10.1182/bloodadvances.2020004106
[24] Frigault MJ, Dietrich J, Gallagher K, et al. Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial[J]. Blood, 139(15): 2306-2315. doi: 10.1182/blood.2021014738
-
计量
- 文章访问数: 1156
- PDF下载数: 735
- 施引文献: 0
下载: